|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gauthier A and Ho M: Role of sorafenib in
the treatment of advanced hepatocellular carcinoma: An update.
Hepatol Res. 43:147–154. 2013. View Article : Google Scholar
|
|
4
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin
SK, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and
safety of sorafenib in patients in the Asia-Pacific region with
advanced hepato-cellular carcinoma: A phase III randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34.
2009. View Article : Google Scholar
|
|
5
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Almhanna K and Philip PA: Safety and
efficacy of sorafenib in the treatment of hepatocellular carcinoma.
Onco Targets Ther. 2:261–267. 2009.PubMed/NCBI
|
|
8
|
Petrini I, Lencioni M, Ricasoli M,
Iannopollo M, Orlandini C, Oliveri F, Bartolozzi C and Ricci S:
Phase II trial of sorafenib in combination with 5-fluorouracil
infusion in advanced hepatocellular carcinoma. Cancer Chemother
Pharmacol. 69:773–780. 2012. View Article : Google Scholar
|
|
9
|
Wang L, Jia D, Duan F, Sun Z, Liu X, Zhou
L, Sun L, Ren S, Ruan Y and Gu J: Combined anti-tumor effects of
IFN-α and sorafenib on hepatocellular carcinoma in vitro and in
vivo. Biochem Biophys Res Commun. 422:687–692. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang Y, Jiang H, Gao H, Kong J, Zhang P,
Hu S, Shi B, Zhang P, Yao M and Li Z: The monoclonal antibody CH12
enhances the sorafenib-mediated growth inhibition of hepatocellular
carcinoma xenografts expressing epidermal growth factor receptor
variant III. Neoplasia. 14:509–518. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greim H, Trülzsch D, Roboz J, Dressler K,
Czygan P, Hutterer F, Schaffner F and Popper H: Mechanism of
cholestasis. 5. Bile acids in normal rat livers and in those after
bile duct ligation. Gastroenterology. 63:837–845. 1972.PubMed/NCBI
|
|
12
|
Alberts DS, Martinez ME, Hess LM, Einspahr
JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK,
Salen G, et al: Phase III trial of ursodeoxycholic acid to prevent
colorectal adenoma recurrence. J Natl Cancer Inst. 97:846–853.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Loddenkemper C, Keller S, Hanski ML, Cao
M, Jahreis G, Stein H, Zeitz M and Hanski C: Prevention of
colitis-associated carcinogenesis in a mouse model by diet
supplementation with ursodeoxycholic acid. Int J Cancer.
118:2750–2757. 2006. View Article : Google Scholar
|
|
14
|
Sabharwal SS and Schumacker PT:
Mitochondrial ROS in cancer: Initiators, amplifiers or an Achilles'
heel? Nat Rev Cancer. 14:709–721. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan BJ and Chiu GN: Role of oxidative
stress, endoplasmic reticulum stress and ERK activation in
triptolide-induced apoptosis. Int J Oncol. 42:1605–1612. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen J, Wang J, Lin L, He L, Wu Y, Zhang
L, Yi Z, Chen Y, Pang X and Liu M: Inhibition of STAT3 signaling
pathway by nitidine chloride suppressed the angiogenesis and growth
of human gastric cancer. Mol Cancer Ther. 11:277–287. 2012.
View Article : Google Scholar
|
|
17
|
Ryu K, Susa M, Choy E, Yang C, Hornicek
FJ, Mankin HJ and Duan Z: Oleanane triterpenoid CDDO-Me induces
apoptosis in multidrug resistant osteosarcoma cells through
inhibition of Stat3 pathway. BMC Cancer. 10:1872010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wake MS and Watson CJ: STAT3 the
oncogene-still eluding therapy? FEBS J. 282:2600–2611. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gu FM, Li QL, Gao Q, Jiang JH, Huang XY,
Pan JF, Fan J and Zhou J: Sorafenib inhibits growth and metastasis
of hepatocellular carcinoma by blocking STAT3. World J
Gastroenterol. 17:3922–3932. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Blechacz BR, Smoot RL, Bronk SF, Werneburg
NW, Sirica AE and Gores GJ: Sorafenib inhibits signal transducer
and activator of transcription-3 signaling in cholangiocarcinoma
cells by activating the phosphatase shatterproof 2. Hepatology.
50:1861–1870. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nordberg J and Arner ES: Reactive oxygen
species, antioxidants, and the mammalian thioredoxin system. Free
Radic Biol Med. 31:1287–1312. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Circu ML and Aw TY: Reactive oxygen
species, cellular redox systems, and apoptosis. Free Radic Biol
Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lim SC, Duong HQ, Choi JE, Lee TB, Kang
JH, Oh SH and Han SI: Lipid raft-dependent death receptor 5 (DR5)
expression and activation are critical for ursodeoxycholic
acid-induced apoptosis in gastric cancer cells. Carcinogenesis.
32:723–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Coriat R, Nicco C, Chereau C, Mir O,
Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F and
Batteux F: Sorafenib-induced hepatocellular carcinoma cell death
depends on reactive oxygen species production in vitro and in vivo.
Mol Cancer Ther. 11:2284–2293. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Park BH, Lim JE, Jeon HG, Seo SI, Lee HM,
Choi HY, Jeon SS and Jeong BC: Curcumin potentiates antitumor
activity of cisplatin in bladder cancer cell lines via ROS-mediated
activation of ERK1/2. Oncotarget. 7:63870–63886. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zuo D, Zhou Z, Wang H, Zhang T, Zang J,
Yin F, Sun W, Chen J, Duan L, Xu J, et al: Alternol, a natural
compound, exerts an anti-tumour effect on osteosarcoma by
modulating of STAT3 and ROS/MAPK signalling pathways. J Cell Mol
Med. 21:208–221. 2017. View Article : Google Scholar
|
|
27
|
Pang L, Zhao X, Liu W, Deng J, Tan X and
Qiu L: Anticancer effect of ursodeoxycholic acid in human oral
squamous carcinoma HSC-3 cells through the caspases. Nutrients.
7:3200–3218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tsagarakis NJ, Drygiannakis I, Batistakis
AG, Kolios G and Kouroumalis EA: A concentration-dependent effect
of ursodeoxycholate on apoptosis and caspases activities of HepG2
hepatocellular carcinoma cells. Eur J Pharmacol. 640:1–7. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krishna-Subramanian S, Hanski ML,
Loddenkemper C, Choudhary B, Pagès G, Zeitz M and Hanski C: UDCA
slows down intestinal cell proliferation by inducing high and
sustained ERK phosphorylation. Int J Cancer. 130:2771–2782. 2012.
View Article : Google Scholar
|
